Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types (AcSé)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03012581
Recruitment Status : Active, not recruiting
First Posted : January 6, 2017
Last Update Posted : March 29, 2022
National Cancer Institute, France
Ligue contre le cancer, France
Bristol-Myers Squibb
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : December 2023